Physician profile
Eric C Ehle
NPI 1114238839
$3,089.69
in general payments reported to CMS, 2019-2025
30 companies · $340 in 2025
The $340 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $103 · 2020: $18.70 · 2021: $21.53 · 2022: $1,914 · 2023: $271 · 2024: $421 · 2025: $340.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,032.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,031.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bard Peripheral Vascular, INC. | $1,266.25 | 2022 | |
| Boston Scientific Corporation | $517.18 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $168.25 | 2019-2024 | Xarelto |
| Lilly USA, LLC | $140.74 | 2022-2025 | Zepbound, Jardiance, Mounjaro |
| Astellas Pharma US INC | $136.61 | 2019-2023 | Veozah |
| Cleerly, INC. | $128.18 | 2024-2025 | Cleerly Ischemia, Cleerly Labs |
| Genzyme Corporation | $87.51 | 2024-2025 | |
| Lundbeck LLC | $64.11 | 2024-2025 | Vyepti |
| Astrazeneca Pharmaceuticals LP | $61.41 | 2023-2025 | Airsupra, Breztri |
| Takeda Pharmaceuticals U.S.A., INC. | $61.38 | 2023-2024 | Trintellix, Glassia |
| Pfizer INC. | $50.11 | 2022-2024 | |
| Amgen INC. | $45.49 | 2023 | Repatha, Otezla, Evenity |
| Bioventus LLC | $35.03 | 2025 | Xcell |
| Abbott Laboratories | $31.50 | 2022-2024 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $23.81 | 2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $23.57 | 2023 | |
| Sanofi Pasteur INC. | $23.15 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $21.53 | 2021 | |
| Alnylam Pharmaceuticals INC. | $19.79 | 2024 | Givlaari |
| Teva Pharmaceuticals USA, INC. | $19.69 | 2025 | Austedo Xr |
| Dexcom, INC. | $19.56 | 2024 | Dexcom G6 Transmitter |
| Acella Pharmaceuticals, LLC | $18.57 | 2025 | NP Thyroid 60 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.30 | 2019 | |
| Phathom Pharmaceuticals, INC. | $18.24 | 2025 | Voquezna |
| Ibsa Pharma INC. | $16.59 | 2023 | Tirosint, Licart |
| 3b Medical, INC. | $15.85 | 2024 | Luna |
| Allergan, INC. | $15.65 | 2019 | |
| Xeris Pharmaceuticals, INC. | $14.74 | 2022 | |
| Phadia US INC. | $13.80 | 2025 | Immunocap |
| Endo Pharmaceuticals INC. | $13.10 | 2023 | Xiaflex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Ehle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.